Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent ...